Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials

UCLA's Jonsson Comprehensive Cancer Center

UCLA's Jonsson Comprehensive Cancer Center
JCCC: A Comprehensive Cancer Center
JCCC Member Directory
Calendar
Contact Us
Map and Directions to JCCC
Social Media
Connect via Mobile
Privacy Practices
 
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Timothy Cloughesy, M.D.
Timothy Cloughesy, M.D.

Specialty:

Neurology

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Professor and Director, Department of Neurology, Neurological Services, Neuro-Oncology Program
Physician, Department of Neurology
Member, Brain Research Institute
Member, JCCC Cancer Molecular Imaging Program Area
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Fellowship:
Neurological Oncology, Memorial Sloan-Kettering Cancer Center, 1991 - 1992
Residency:
Neurology, UCLA School of Medicine, 1988 - 1991
Internship:
Neurology, Maricopa Medical Center, 1987 - 1988
Medical Degree:
M.D., Tulane University School of Medicine, 1987

Contact Information:

Neuro-Oncology Program:
(310) 825-5321 Information
(310) 206-6909 New patient appointments and referral
Email:
tcloughe@ucla.edu

Practice Information:

Clinical Interest(s):
Brain Tumor
Neuro Oncology

Scientific Interest(s):

Dr. Timothy Cloughesy's research focuses on clinical trials in brain cancer using targeted molecular therapies with novel clinical trial design. He has developed a brain cancer bioinformatics database which combines clinical outcomes, imaging and molecular analysis to enhance translational research. His goal is to use molecular biology to provide individualized care for brain cancer patients.

Selected Cancer-Related Publications:

Carlson MR, Pope WB, Horvath S, Braunstein JG, Nghiemphu P, Tso CL, Mellinghoff I, Lai A, Liau LM, Mischel PS, Dong J, Nelson SF, Cloughesy TF. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res. 2007; 13(9): 2592-8.

Schiepers C, Chen W, Dahlbom M, Cloughesy T, Hoh CK, Huang SC. (18)F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging. 2007; 34(7): 1003-11.

Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF. Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res. 2006; 4(9): 607-19.

Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells. Cancer Res. 2006; 66(16): 7864-7869.

Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006; 12(16): 4899-907.

In the News: